Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name | Regorafenib |
Latin Name | 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide |
CAS NO | 755037-03-7 |
MF | C21H15ClF4N4O3 |
MW | 482.82 |
Assay | 99% |
Shelf life | 2 Years |
Form | White Powder |
Brand | Sonwu |
Place of origin | China |
1. Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK).
2. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung.
Capecitabine | Everolimus | Afatinib | Vandetanib | Gefitinib |
Temozolomid | Rapamycin | Axitinib | Sorafenib tosylate | Cediranib |
Cabozantinib | Selumetinib | Crizotinib | Sunitinib malate | Erlotinib |
Crizotinib | Lapatinib | Debrafenib | Cabazitaxel | Ponatinib |
1. Customs clearance